Secondary cost analysis of the phase 3 RADICAL trial in lentigo maligna (118 patients completing treatment): health care system cost per patient was US$2673.43 for radiotherapy vs US$72.50 for topical imiquimod; societal costs were US$4379.22 vs US$697.94.
RCTn = 118
Guitera et al. A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making